Answers are grounded in this paper and cite their sources.
Background: SARS-Cov-2 targets the peptidase ACE2, a key component of the renin-angiotensin system (RAS), which directly regulates the balance of the vasoconstrictor/inflammatory peptide Ang II and the vasodilator/anti-inflammatory peptide Ang-(1-7). Few studies have quantified the circulating elements of the RAS longitudinally in SARS-Cov-2 infection and their association with COVID-19 outcomes. Objective: Evaluate the association of circulating RAS enzymes with mortality in critically ill patients with COVID-19. Methods: We quantified serum ACE and ACE2 concentrations by ELISA among 111 patients hospitalized for confirmed SARS-Cov-2 infection with new onset hypoxemia who were randomized to the placebo arm of the ACTIV-4 Host Tissue trials investigating RAS pathway interventions. Serum was collected at baseline/randomization (Day 0) and 1, 3, and 5 days after randomization. We used multivariable Cox regression to estimate the association of baseline and longitudinal ACE and ACE2 with 90-day mortality. Hazard ratios (HR) for RAS enzyme concentrations were adjusted for age, sex, race/ethnicity, baseline level of O 2 support, obesity, hypertension, RAS inhibitor use prior to admission, and vasopressor use within 7 days of admission. Results: Participants were aged 18-90 (mean [SD] = 55 [14]) years, 62% male, 42% non-White, with 58% and 48% prevalence of obesity and hypertension, respectively. There were 22 (20%) deaths over 90 days of follow-up (median [25%, 75%] time to event = 16 [9, 29] days). Relative to participants with values below the sample median, those with higher Day 0 ACE2 (>4.9 pM; adjusted HR [95% CI] = 0.07 [0.02, 0.33]) and ACE2/ACE ratio (>6.0*10 -3 ; adjusted HR = 0.08 [0.01, 0.39]) had significantly lower mortality. Similarly, when analyzed as continuous, log 2 -normalized, time-varying predictors from Day 0 to Day 5, two-fold increments in ACE2 (adjusted HR = 0.81 [0.69, 0.96]) and ACE2/ACE ratio (adjusted HR = 0.78 [0.64, 0.96]) over this period were associated with lower mortality. Results did not differ by hypertension status (interaction p=0.385 and 0.278 for Day 0 ACE2 and ACE2/ACE ratio, respectively, and p=0.714 and 0.457 for time-varying ACE2 and ACE2/ACE ratio, respectively). In contrast, neither ACE levels at Day 0 (>1.3 nM; adjusted HR = 1.23 [0.41, 3.67]) nor time-varying ACE (adjusted HR = 1.21 [0.75, 1.95]) were associated with mortality. Conclusions: Higher baseline and longitudinal serum ACE2 levels, but not ACE, were associated with markedly reduced mortality among hospitalized patients with COVID-19, consistent with a protective role for ACE2. Whether serum ACE2 levels arise from tissue ACE2 shedding, thus binding less virus to tissue, should be explored further. A better understanding of the RAS timecourse in severe COVID-19 illness could identify patients at greater risk for adverse outcomes and inform targeted treatment strategies.
No takes yet. Share an insight, caveat, or question.
Schaich et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: